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Abstract
Background/Aims: High-fat dietary intake and low physical activity lead to
insulin resistance, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic
steatohepatitis (NASH). Recent studies have shown an effect of glucagon-like
peptide-1 (GLP-1) on hepatic glucose metabolism, although GLP-1 receptors
(GLP-1r) have not been found in human livers. The aim of this study was to
investigate the presence of hepatic GLP-1r and the effect of exenatide, a GLP-1
analogue, on hepatic signalling. Methods: The expression of GLP-1r was
evaluated in human liver biopsies and in the livers of high-fat diet-treated
rats. The effect of exenatide (100 nM) was evaluated in hepatic cells of rats fed
3 months with the high-fat diet. Results: GLP-1r is expressed in human
hepatocytes, although reduced in patients with NASH. Similarly, in rats with
NASH resulted from 3 months of the high-fat diet, we found a decreased
expression of GLP-1r and peroxisome proliferator-activated receptor g
(PPARg), and reduced peroxisome proliferator-activated receptor a (PPARa)
activity. Incubation of hepatocytes with exenatide increased PPARg expression,
which also exerted an insulin-sensitizing action by reducing JNK phosphor-
ylation. Moreover, exenatide increased protein kinase A (PKA) activity, Akt
and AMPK phosphorylation and determined a PKA-dependent increase of
PPARa activity. Conclusions: GLP-1 has a direct effect on hepatocytes, by
activating genes involved in fatty acid b-oxidation and insulin sensitivity.
GLP-1 analogues could be a promising treatment approach to improve hepatic
insulin resistance in patients with NAFLD/NASH.
Hepatic insulin resistance is the main determinant of not
only fasting but also postprandial hyperglycaemia. Subjects
with nonalcoholic fatty liver disease (NAFLD) have been
shown to be very insulin resistant at the level of the liver,
even when they are lean and without the features of
metabolic syndrome (1). NAFLD represents the hepatic
manifestation of metabolic syndrome, leading to nonalco-
holic steatohepatitis (NASH), cirrhosis and hepatocellular
carcinoma (2). The prevalence of NAFLD and NASH,
although not known, is increasing in western countries
owing to high dietary fat intake and low physical activity
and NAFLD/NASH is often associated with obesity and
diabetes (3). Glucagon-like peptide-1 (GLP-1) analogues,
recently approved for the treatment of diabetic hypergly-
caemia (4), have also been proposed as a treatment for the
liver injury associated with hepatic steatosis (5).
In this respect, GLP-1 is an incretin hormone secreted
by enteroendocrine L-cells in response to ingested nu-
trients and is rapidly degraded by the dipeptidyl pepti-
dase-4 (DPP-IV) enzyme (6). The first action of GLP-1 is
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the potentiation of glucose-stimulated insulin secretion
in b-cells, mediated by activation of its seven-transmem-
brane domain G-protein-coupled receptors (GLP-1r)
(7). As a consequence, the GLP-1r selective agonist
exenatide is now used as a novel antidiabetic therapy. A
direct effect of GLP-1 on organs other than pancreas has
also been postulated (8). GLP-1r has been found in
pancreas, intestine, lung, kidney, breast, heart and brain
(9) and is also expressed in nerves that innervate hepato-
cytes (10). Recently, GLP-1r expression has been found in
cultured rodent hepatocytes and a GLP-1r agonist was
able to reduce hepatic steatosis in ob/ob mice (11). In the
present study, we demonstrated the presence of GLP-1r
in human liver and in a human hepatoma cell line
(HepG2), and that GLP-1r expression is reduced in
patients with NASH. Starting from this result and using
an experimental model of NASH in rats, we demon-
strated that despite a reduction in expression, hepatic
GLP-1 receptors could respond to treatment with exena-
tide that directly affects the expression of hepatic genes
involved in glucose and lipid metabolism.
Material and methods
Patients
Normal human liver was obtained from six patients who
underwent hepatic resection for focal nodular hyperplasia
or hepatic adenoma. Pathological samples were obtained,
in excess for diagnostic histological purposes, from 19
patients with biopsy-proven NASH. The protocol of data
collection was part of the common clinical practice in the
Clinica di Gastroenterologia, Universita` Politecnica delle
Marche-Ospedali Riuniti Ancona. All subjects were asked
to give their informed consent for the use of personal data,
analyses and liver biopsy at the time of admission. This
specific study was approved by the institutional review
boards of Ospedali Riuniti Ancona, regulating noninter-
ventional studies and by the Italian Ministry of Health.
Diagnosis of NAFLD was performed according to the
statement of the American Gastroenterological Association
(12). The diagnosis of NASH and the degree of liver injury
were determined according to Kleiner et al. (13).
Normal human pancreas, used as a positive control for
GLP-1r expression, was obtained during pancreatectomy
for pancreatic adenocarcinoma.
Animals
The experiment was performed following the guidelines of
the local committee for care and use of laboratory animals.
Male Sprague–Dawley CD rats (100–120 g body weight at
the beginning of the treatment) (Charles River Labora-
tories, Como, Italy) were fed either a chow pellet diet (5%
of energy derived from fat, 18% from proteins and 77%
from carbohydrates; 3.3 kcal/g) (Harlan Italy, San Pietro al
Natisone, UD, Italy) or a high-fat pellet diet (high-fat diet)
(58% of energy derived from fat, 18% from protein and
24% from carbohydrates; 5.6 kcal/g) (Laboratorio Dottor
Piccioni, Gessate, Milano, Italy) (14, 15) twice weekly. Rats
were housed in individual cages and the amount of food
consumed was recorded to determine the amount of
calories introduced. We have shown previously that this
diet was able to induce the features of NASH (perivenular
steatosis, hepatocellular injury and lobular inflammation)
at 1 and 3 months of feeding, associated with an increased
matrix deposition at 6 months (15). Rats were sacrificed at
1 and 3 months of treatment (n= 10 for each time point)
after an overnight fasting. Portal blood was obtained before
liver removal. After liver removal, the epididymal fat was
removed to measure visceral adipose tissue, and its weight
and volume were recorded (16). Hepatic lipids were
extracted as described previously (17). The lipid extracts
were resuspended in methanol and used for the evaluation
of cholesterol and triglycerides levels by commercial kits
from Sigma Chemical Co. (St. Louis, MO, USA). Plasma
insulin and glucose were determined using the commer-
cially available kit. Rat brain, used as a positive control for
GLP1-r expression, was obtained at the time of sacrifice.
Reagents
Reagents were purchased from Sigma Chemical Co. unless
otherwise indicated. The following antibodies were used:
anti-diphosphorylated extracellular signal-regulated kinase
(ERK)1/2 (pERK) (1:5000 final dilution), anti-Ser473 phos-
phorylated Akt (pAkt) (1:1000), anti-Thr183/Tyr185 phos-
phorylated JNK (pJNK) (1:800), anti-Thr172 phosphorylated
AMPK (Cell Signaling Technology, Danvers, MA, USA)
(pAMPK) (1:1000), anti-GLP-1r (1:2000, Alpha Diagnostic
Intl, San Antonio, TX, USA) and anti-b-actin (1:10 000).
Cell preparation and treatment
Hepatocytes were isolated from high-fat diet rats be-
tween 1 and 3 months and cultured on Matrigel-coated
six-well plates (0.5 106 cells/well) in Iscove’s modified
Dulbecco’s medium supplemented with 10% fetal bovine
serum (FBS), 2mmol/L glutamine and 1% antibiotic–
antifungal solution (IMDM) as described previously
(18). After 4 h, cells were washed with phosphate-
buffered saline (PBS) and incubated overnight with
IMDM containing 0.5% FBS. HepG2 cells were kindly
provided by Prof. D. Alvaro (University ‘La Sapienza’,
Rome, Italy) and cultured in Dulbecco’s MEM (Amimed,
Basel, Switzerland), containing pennicillin/streptomycin
(1%), nonessential amino acids (1%), sodium pyruvate
(1%), L-glutamine (1%) and supplemented with 10%
FBS. Before treatment, HepG2 were kept overnight in the
same medium containing 0.5% FBS. Cells were incu-
bated with exenatide (purchased from American Peptide
Inc., Sunnyvale, CA, USA) at 10 and 100 nM) (19) for the
indicated period of time and treated as indicated below.
In parallel experiments, cells were also pre-incubated for
30min at 37 1C with either Rp-c-AMP (100 mmol/L,
a protein kinase A (PKA) inhibitor), or wortmannin
(100 nM, a PI3K inhibitor), or compound C (20 mM, an
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AMPK inhibitor), or GW9662 (1 mM, 2 h pretreatment, a
peroxisome proliferator-activated receptor g (PPARg)
inhibitor), or MK886 [10 mM, 2 h pretreatment, a per-
oxisome proliferator-activated receptor a (PPARa) in-
hibitor] followed by incubation with exenatide (18–22).
Rp-c-AMP and compound C were from Calbiochem
(Milan, Italy), while wortmannin, GW9662 and MK886
were from Sigma Chemical Co.
Western blot
The cells were lysed in PBS containing 1% Igepal CA-630,
0.5% sodium deoxycholate, 0.1% SDS, 10mg/ml PMSF,
30ml//ml aprotinin and, 100mM sodium orthovanadate.
Twenty micrograms of protein was fractionated by elec-
trophoresis on 10% (w/v) SDS-PAGE and electrophoreti-
cally transferred to a nitrocellulose membrane, using the
iBlotTM Dry Blotting System (Invitrogen, Life Technolo-
gies, Madison, WI, USA). Nitrocellulose sheets were then
incubated with the specific antibody indicated above. The
antigen–antibody complexes were visualized using the
ECL detection system as recommended by the manufac-
turer (Amersham, Arlington Heights, IL, USA). The
intensity of the bands was determined by scanning video
densitometry using the ChemiIimager 4000 low-light
imaging system (Alpha Innotech, San Leandro, CA, USA).
Expression of glucagon-like peptide-1 receptor in the liver
The GLP-1r mRNA expression was assessed by reverse
transcriptase-mediated polymerase chain reaction
(RT-PCR) in human biopsies and rat tissues. Total RNA
was extracted using the TRIzols reagent according to the
manufacturer’s instructions (Invitrogen, Life Technologies).
The integrity of the purified total RNA was confirmed by
ethidium bromide staining after electrophoresis on agarose
gel. Total RNA was converted to cDNA with random
primers using the M-MLV Reverse Transcriptase (Promega,
Madison, WI, USA). PCR was performed using the Plati-
num Taq DNA Polymerase (Invitrogen, Life Technologies).
Primers specific for rat and human GLP-1 receptor were
designed as follows: sense 50-TGTACCTGAGCATAGGC
TGG-30 and antisense 50-GCTCCCAGCTCTTCCGAAAC-
30, sense 50-GAGTGCGAGGAGTCCAAGC-30 and anti-
sense 50-GGTGTCTGAAGCCGAGGAG-30 respectively
(Gene Bank accession number of rat and human mRNA
RefSeq: NM_012728 and NM_002062 respectively). Rat
brain and human pancreas biopsies were used as a positive
control for rat and human GLP-1r respectively. Amplified
products (453 and 142 bp respectively) were subjected
to electrophoresis on 10% acrylamide gel, stained
with ethidium bromide and then visualized on a UV
transilluminator.
Glucagon-like peptide-1 receptor expression was also
evaluated in cultured hepatocytes from high-fat diet
animals by using a specific GLP-1r antibody (1:2000,
Alpha Diagnostic Intl) by Western blot as described
above.
Real-time polymerase chain reaction
Total RNA was extracted from hepatocytes and liver
samples using the TRIzols reagent (Invitrogen, Life Tech-
nologies) following the manufacturer’s protocol. The
integrity of the purified total RNA samples to be used in
real-time PCR was confirmed by ethidium bromide stain-
ing after electrophoresis on agarose gel. First-strand cDNAs
were synthesized from equal amounts of total RNA using
random primers and M-MLV reverse transcriptase (Pro-
mega, Premier Biosoft International, Palo Alto, CA, USA).
Primers for real-time PCR were designed using BEACON
DESIGNER software version 2.12, according to the parameters
outlined in the BioRad iCycler Manual, using reference
mRNA sequences accessed through Gene Bank and as
shown in Table 1. Specificity of primers was confirmed by
BLAST analysis. Real-time PCR for PPARa, PPARg, acyl-
coenzyme A oxidase 1-palmitoyl (ACOX1), liver carnitine
palmitoyltransferase 1A (CPT1A) and GLP-1r mRNA was
performed using the BioRad iCycler iQ Detection System
(BioRad Laboratories Ltd, Hercules, CA, USA) with SYBR
Green fluorophore. The change in fluorescence at every
cycle was monitored and a threshold cycle (CT) above
background for each reaction was calculated. A melt curve
analysis was performed following every run to ensure a
single amplified product for every reaction. All reactions
were carried out in at least duplicate for every sample.
Duplicate negative controls (no template cDNA) were also
run with every experimental plate to assess specificity and
indicate potential contamination. Enolase 1a mRNA was
constantly expressed under all experimental conditions
and was then used as a reference gene for normalization
as published previously (23). The comparative threshold
cycle analysis method (GENEX software; Bio-Rad Labora-
tories Ltd) was used to assess the relative changes in gene
expression compared with that of enolase 1a.
Table 1. Primer sequences used for the real-time polymerase chain
reaction
Genes Primer sequences
PPARa Sense: 50-CTC GGA GGG CTC TGT CAT C-30
Antisense: 50-GGG ACT CAT CTG TAC TGG TGG-30
PPARg Sense: 50-CTC ACA ATG CCA TCA GGT TTG-30
Antisense: 50-CTC GCA GAT CAG CAG ACT C-30
ACOX1 Sense: 50-GCA GAC AGC CAG GTT CTT GAT G-30
Antisense: 50-ACT CGG CAG GTC ATT CAG GTA TG-30
CPT1A Sense: 50-GCT TTG ACA GGT GGT TTG AC-30
Antisense: 50-GGG ATG TTG GGG TTG GT-30
Enolase 1a Sense: 50-TCA AGA TCC ATG CCA GAG AG-30
Antisense: 50-GCC TCG TAG ATG CCA GTG-30
Rat GLP1-r Sense: 50-ACC TGA ACC TGT TTG CGT CC-30
Antisense: 50-AGC CCA GAG AGT CCT GATACG AG-30
Human
GLP1-r
Sense: 50-GAGTGCGAGGAGTCCAAGC-30
Antisense 50-GGTGTCTGAAGCCGAGGAG-30
ACOX1, acyl-coenzyme A oxidase 1-palmitoyl; CPT1A, carnitine palmi-
toyltransferase 1A; GLP1-r, glucagon-like peptide-1 receptor; PPARa,
peroxisome proliferator-activated receptor a; PPARg, peroxisome prolif-
erator-activated receptor g.
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Measurement of protein kinase A activity
Protein kinase A activity was evaluated using the PepTag
assay protein kinase kit (Promega). Effect of exenatide
(EXE, 100 nM) on PKA, ERK, Akt and AMPK activity
was evaluated in cultured hepatocytes isolated from rats
with NASH. Isolated hepatocytes were cultured over-
night in Iscove’s medium containing 0.5% FBS and
then incubated with the same medium containing or
not containing 100 nM exenatide for the indicated period
of time. We also evaluated the effect of the PKA inhibitor
Rp-c-AMP (Rp, 100 mmol/L), PI3K inhibitor wortman-
nin (W, 100 nM) and AMPK inhibitor compound C
(CompC, 20 mM) on PPARa, its downstream genes
ACOX and CPT1A and PPARg mRNA expression in
isolated hepatocytes cultured overnight in Iscove’s
medium containing 0.5% FBS and then incubated for
additional 24 h with the same medium containing or not
100 nM exenatide. In parallel experiments, cells were also
pre-incubated for 30min at 37 1C with either Rp-c-AMP
or wortmannin. Total RNA was extracted and real-time
PCR was performed. Effect of exenatide on JNK phos-
phorylation was evaluated in hepatocytes isolated from
rats with NASH, cultured overnight in Iscove’s medium
containing 0.5% FBS and then incubated for additional
24 h with the same medium containing or not 100 nM
exenatide. In parallel experiments, cells were also pre-
incubated for 2 h at 37 1C with the PPARg inhibitor
GW9662 (20 mM). Protein lysates were obtained and
Western blot was performed. The intensity of the
bands of at least three experiments was then normalized
to that of b-actin.
Measurement of total hepatic fatty acid content
The total amount of fatty acids in cell layers was evaluated
by gas chromatography as reported previously (22).
Statistical analysis
Result data are expressed as mean SD of fold increase
compared with controls and represent at least three
different experiments. Group means were compared by
analysis of variance followed by the Student–Newman–
Keuls test whether the former was significant. A P-value
of o 0.05 was considered statistically significant.
Results
Glucagon-like peptide-1 receptor expression in human
liver
The presence of GLP-1r in the liver has been questioned,
especially in humans. Thus, we first evaluated the expres-
sion of GLP-1r in samples of patients with NASH and in
normal livers. Using RT-PCR a single 142 bp band was
detected both in human pancreas (used as positive
control) and in all liver samples (Fig. 1A). A single
142 bp band was also detected in the human hepatoma
cell line HepG2 as well as in pancreas (Fig. 1B). When
quantified by real-time PCR, GLP-1r expression was
reduced in the liver of patients with NASH compared
with normal samples (Fig. 1B).
To confirm that hepatocytes express GLP1-r at the
protein level, tissue and cell lysates were tested by Western
blot. A single 53 kDa band was detected in cell lysate from
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Fig. 1. Assessment of presence of glucagon-like peptide-1 receptor (GLP-1r) mRNA in human livers. (A) GLP-1r mRNA expression was assessed
by polymerase chain reaction (PCR) in human pancreas (positive control) and in the whole human liver. 1: pancreas; 2: liver; 3: no template
product; 4: 100 bp ladder. (B) GLP1-r mRNA expression was assessed by PCR in human pancreas (positive control) and HepG2 cells. 1: 100 bp
ladder; 2: pancreas; 3: no template product; 4: HepG2 cells. (C) Real-time PCR for GLP1r mRNA was performed in six normal human livers
(white bar) and in nineteen patients with NASH (black bar). Data are expressed as mean SD of fold increase compared with controls.
Po0.05 vs controls.
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human pancreas and rat brain, used as a positive control, as
well as from HepG2 cells, while no bands were observed
when human serum albumin was used (Fig. 2A). Protein
expression was then quantified in the liver of patients with
NASH and in normal human samples, showing again a
significant decrease in NASH (Fig. 2B and C).
Metabolic and histological hepatic changes induced by
high-fat diet
To induce NASH in rats, we fed animals a high-fat or a
chow diet, as described previously (15). Rats fed with high-
fat diet consumed significantly more calories (98.4 9.5 vs
75.3 7.2, Po 0.001 vs controls) and increased body
weight (1 month: 341.7 18.2 vs 287.3 15.0 and 3
months: 467.3 14 vs 397.9 24, Po 0.05 vs controls)
in comparison to chow rats. The increase in weight
was associated with hepatic steatosis (13.3 0.8 and
16.5 2.1mg of triglycerides/g after 1 and 3 months of
high-fat diet vs 3.2 0.3 in controls, Po 0.05), visceral
obesity with higher epididymal fat weight (1.6 0.4 vs
4.5 0.7 g and 3.2 0.5 vs 7.3 0.8 g at 1 and 3 months,
respectively, Po 0.05 vs controls) and development of
insulin resistance, as shown by higher insulin (0.7 0.07
and 0.7 0.05mg/L at 1 and 3 months, respectively, vs
0.2 0.03, Po 0.05) and glucose (147.1 18.9 and
151.0 15.7 vs 111.8 12.3mg/dl, Po 0.05) values in the
portal blood compared with chow rats. Thus, high-fat diet
was able to induce visceral/hepatic fat accumulation and
insulin resistance even in nongenetically modified animals.
No histological signs of liver injury were observed in
rats fed the chow diet. After 3 months of high-fat diet,
steatosis affected most of the hepatocytes, ballooning
was diffusely present, and foci of mixed inflammatory
cell infiltration and hepatocyte necrosis or apoptosis
appeared throughout the lobules.
High-fat diet effect on GLP-1 receptor, peroxisome
proliferator-activated receptors and lipid oxidation
gene expression
To study the effect of high-fat diet on hepatic expression
of GLP-1r, whole liver and hepatocytes were obtained
from rats fed chow or high-fat diet up to 3 months. GLP-
1r expression was evaluated in rat liver by PCR: a single
453 bp band was detected in rat brain (used as positive
control) and in all liver samples (Fig. 3A). Real-time PCR
showed that high-fat diet significantly decreased GLP-1r
mRNA expression already after 1 month of high-fat diet
confirming the association between NASH and reduced
expression of GLP-1r (Fig. 3B).
To confirm that rat hepatocytes also express GLP1-r at
the protein level, tissue and cell lysates were tested by
Western blot. A single 53 kDa band was detected in cell
lysates from rat brain, as well as from either the whole liver
and isolated rat hepatocytes (Fig. 3C). Protein expression
was then quantified in the liver of chow- and high-fat diet-
treated rats, showing again that GLP1-r expression is
reduced in the presence of NASH (Fig. 3D and E).
High-fat diet significantly reduced PPARg expression
in the whole liver (Fig. 4). Previously we have shown that
high-fat diet decreased PPARa activity, as shown by
reduced nuclear translocation in the whole liver (15).
Consistent with this, expression of PPARa target genes
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Fig. 2. Assessment of presence of glucagon-like peptide-1 (GLP1-r) at the protein level in human livers. (A) GLP1-r was assessed by Western
blot in human pancreas and rat brain (positive controls), and in HepG2 cells. 1: human pancreas; 2: human serum albumin; 3: HepG2 cells;
4: rat brain. (B) GLP1-r protein expression was assessed by Western blot in patients with nonalcoholic steatohepatitis (NASH) and in normal
human liver samples. (C) Densitometric analysis of the intensity of the bands in normal human livers (white bar) and in patients with NASH
(black bar). Data are expressed as mean SD of fold increase compared to controls. Po 0.05 vs controls.
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Fig. 4. Effect of high-fat diet on mRNA expression in the whole rat liver of peroxisome proliferator-activated receptor g (PPARg), and of peroxisome
proliferator-activated receptor g (PPARa) downstream genes acyl-coenzyme A oxidase 1-palmitoyl (ACOX1) and carnitine palmitoyltransferase 1A
(CPT1A). Total RNA was extracted from the liver of control (white bars) and high-fat diet-treated rats (black bars) at the different time points, and
quantified by real-time PCR. Data are expressed as mean SD of fold increase compared to controls. Po0.05 vs controls.
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ACOX1 (a rate-limiting enzyme in peroxisomal FFA b-
oxidation) and CPT1A (a key enzyme in mitochondrial
b-oxidation of FFA) was decreased in high-fat diet
compared with chow rats (Fig. 4).
Effect of exenatide on peroxisome proliferator-activated
receptors and lipid oxidation modifications induced by
high-fat diet
We investigated the role of GLP-1 on the alteration of
intracellular signalling and gene expression in hepato-
cytes isolated from rats treated with high-fat diet. We
firstly looked at expression of GLP-1r in hepatic par-
enchymal cells (i.e. hepatocytes). Using Western blot, the
reactive band was evident in freshly isolated hepatocytes
from high-fat diet rats, and was maintained up to 48 h in
culture, thus indicating the possibility to respond to the
specific ligand (Fig. 5A). When hepatocytes were isolated
from high-fat diet rats, a decrease in PPARg
( 73.4 5.2%, Po 0.05), ACOX1 ( 62.3 7.1%,
Po 0.05) and CPT1A ( 48.2 4.6%, Po 0.01) gene
expression was observed compared with hepatocytes
isolated from chow fed animals, thus resembling in
parallel the observations in the whole liver. In hepato-
cytes isolated from high-fat diet fed rats, real-time PCR
showed that 24 h incubation with 10 and 100 nM exena-
tide significantly increased PPARg and PPARa expres-
sion, and mRNA levels of its downstream genes ACOX1
and CPT1A (Fig. 5B–E). A similar effect was observed
when exenatide was incubated in hepatocytes isolated
from rats fed the chow diet (data not shown). From this
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Fig. 5. (A) Glucagon-like peptide-1 receptor (GLP-1r) expression in cultured hepatocytes isolated from rats with nonalcoholic steatohepatitis
(NASH). (B–E) Effect of exenatide on mRNA expression of peroxisome proliferator-activated receptor g (PPARg), peroxisome proliferator-
activated receptor a (PPARa) and its downstream genes acyl-coenzyme A oxidase 1-palmitoyl (ACOX1) and carnitine palmitoyltransferase 1A
(CPT1A) in cultured hepatocytes isolated from rats with NASH. Hepatocytes were isolated from high-fat diet-treated rats, cultured overnight
and then incubated with the same medium containing (black bars) or not (white bars, control) exenatide for 24 h. Mean SD of fold increase in
exenatide-incubated hepatocytes compared with controls (i.e. no exenatide incubation) and represent at least three different experiments.
Po 0.05 vs controls.
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point on, only 100 nM exenatide was used. No effect on
gene expression was induced by exenatide incubation at
earlier time points (i.e. 3–6 h of incubation). Further-
more, exenatide reduced by 30% the total amount of
fatty acids in hepatocytes isolated from rats treated with
high-fat diet (59.2 12.5 vs 41.7 10.6mg fatty acids/g
dry pellet, Po 0.05)
Effect of exenatide on hepatic intracellular signalling
Glucagon-like peptide-1 receptor belongs to the G-
protein-coupled receptors that, upon ligand binding,
induce PKA activation through cAMP. Incubation with
exenatide of hepatocytes from rats with NASH resulted
in a marked increase in active PKA formation, starting at
10min of incubation (Fig. 6A and B). Exenatide did not
affect ERK phosphorylation (Fig. 6C and D), while
increased phosphorylation of Akt and AMPK starting at
30 and 10min respectively (Fig. 6C and Fig. 6E and F).
When NASH hepatocytes were incubated with exenatide
for 30min in the presence or not of specific inhibitors,
Akt phosphorylation returned down to control value
(Fig. 7A and B). No effect was induced on AMPK
phosphorylation by exenatide, indicating that PI3K and
AMPK pathways are independently activated by this
GLP-1 analogue (Fig. 7A–C).
Next we evaluated the effect of PI3K and AMPK
activation by exenatide on PPARs activity and expres-
sion. Both the PKA inhibitor Rp-c-AMP and the PI3K-
inhibitor wortmannin reduced exenatide-stimulated
PPARg mRNA expression (Fig. 8A). Furthermore, both
inhibitors reduced, ACOX1 and CPT1A gene expression,
consistent with decreased PPARa activity, without
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Fig. 6. Effect of exenatide on PKA (A, B), ERK (C, D), Akt (C–E) and AMPK (C–F) activity, in cultured hepatocytes isolated from rats with
nonalcoholic steatohepatitis (NASH). Hepatocytes were isolated from high-fat diet-treated rats, cultured overnight and then incubated with
the same medium containing (black bars) or not (white bars) 100 nM exenatide for the indicated period of time. Protein lysates were obtained
and Western blot was performed. The intensity of the bands was normalized to that of b-actin and data are expressed as mean SD of fold
increase compared with controls. aPKA, active PKA; iPKA, inactive PKA. Po0.05 vs controls.
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affecting its mRNA level (Fig. 8B). Finally, the AMPK-
inhibitor compound-C similarly reduced ACOX1 and
CPT1A gene expression, and PPARg mRNA levels, in-
dicating that both the PI3K and the AMPK pathways are
involved in GLP-1r signalling (Fig. 6C and D).
Previously we have observed a progressive increase in
JNK1/2 Thr183/Tyr185 phosphorylation in the whole liver
starting at 1 month of high-fat diet (15). Here we found
that GLP-1r activation was able to reduce JNK phosphor-
ylation in hepatocytes isolated from this in vivomodel of
NASH. This effect was mediated by PPARg, as its specific
inhibitor GW9662 abolished this effect, while the PPARa
inhibitor MK886 had no effect (Fig. 9A and B).
Discussion
We have studied the effect of the GLP-1 activator,
exenatide, on hepatocytes with NASH. NAFLD and
NASH are characterized by impaired fatty acid oxidation
and insulin resistance (1, 24, 25) and for such a reason
they are now considered the hepatic feature of the
metabolic syndrome (2). The mechanisms that lead to
hepatic triglyceride accumulation and hepatic insulin
resistance are complex and mostly unknown. At the
moment no therapy for NAFLD/NASH has been estab-
lished. One of the most promising approach is the use of
agents that improve glucose tolerance and insulin sensi-
tivity (26).
Glucagon-like peptide-1 analogues are new drugs
approved for the treatment of diabetic hyperglycaemia.
GLP-1 is an incretin hormone secreted by the intestine in
response to a meal and rapidly degraded by the action of
DPP-IV, resulting in an in vivo half-life of GLP-1 of
approximately 2min. The principal action of GLP-1 is
the potentiation of glucose-stimulated insulin secretion
in b-cells (6, 7), thus improving glucose disposal by
increased insulin release. In type 2 diabetic and in obese
subjects, GLP-1 concentrations are reduced (4, 27, 28).
GLP-1 receptors have been found in pancreatic a- and
b-cells, proximal intestinal tract, muscle (29), adipose
tissue (30), nerve terminals in the hepatic portal bed
(10), heart and brain (31). Several studies have found
that GLP-1 can modulate hepatic glucose metabolism
(10, 32–35) and that ob/ob mice treated with a recombi-
nant adenovirus expressing GLP-1, exhibit reduced glu-
cose production and reduced expression of enzymes
related to gluconeogenesis and de novo lipogenesis (36).
When exenatide was tested on glycaemic control, body
weight and cardiometabolic markers in a population of
patients with type 2 diabetes, a significant reduction in
ALT values was also observed (5). As the expression of
GLP1-r in the liver was questioned (7, 34), we firstly
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Fig. 7. Effect of exenatide, the protein kinase A (PKA)-inhibitor Rp-c-AMP (Rp, 100mmol/L), and the PI3Kinhibitor wortmannin (W, 100 nM) on
pAKT (A, B) and pAMPK (A, C) in cultured hepatocytes isolated from rats with nonalcoholic steatohepatitis (NASH). Isolated hepatocytes were
cultured overnight and then incubated with the same medium containing (black bars) or not (white bars, control) 100 nM exenatide for 30 min.
Protein lysates were obtained and Western blot was performed. The intensity of the bands was normalized to that of b-actin and data are
expressed as mean SD of fold increase compared to controls. Po 0.05 vs controls.
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evaluated the expression of GLP-1r in liver biopsy of
patients with NASH and controls and found that, con-
trary to what was reported previously (31), GLP-1
receptor is present in the human liver, but its level
(measured by both real-time PCR and Western blot)
was decreased in patients with NASH (Fig. 1). Our data
thus expand, in human patients, previous observations
from Ding et al. (37), who found the receptor, at the
protein level, in rat hepatocytes, and that treatment with
exenatide ameliorates hepatic steatosis.
Our hypothesis is that GLP-1r could be implicated in
hepatic insulin resistance and that long-acting GLP-1r
activators, such as exenatide, could be used for the
treatment of NASH/NAFLD. We used an animal model
of diet-induced NASH to evaluate expressions of genes
implicated in hepatic insulin resistance and fatty acid
oxidation as the size of human liver biopsies does not
allow the evaluation of the signalling cascade nor hepa-
tocyte culture (15). NASH was obtained after 3 months
of high-fat diet in nongenetically modified rats, as been
shown previously (15). Expression of GLP-1r was sig-
nificantly reduced already after 1 month of high-fat diet,
similarly to what was observed in the liver of patients
with NASH. This could be one of the causes of hepatic
insulin resistance observed in patients with NAFLD/
NASH (3) as also shown by a recent article from Ayala
et al. (38) that found that mice lacking the GLP-1
receptor exhibit normal peripheral insulin sensitivity
but hepatic insulin resistance.
One of the main causes of NASH is free fatty acids
(FFA) overload towards the liver (either from peripheral
and visceral lipolysis, de novo lipogenesis or high-fat diet)
(24, 39, 40). If overload of FFAs to the organs do not
stimulate their own oxidation, the surplus of fat is stored
not only in white adipose tissue, but also as ectopic fat in
liver, heart and muscle, promoting lipotoxicity and
insulin resistance (24, 41). In subjects with NAFLD
hepatic and total FFA oxidation has been found either
similar or increased compared with subjects without
NAFLD (25, 40) but correlated to liver fat content (40),
indicating that the system is not responding adequately
to the increased FFA flux, probably because of the
saturation process. Several cellular mechanisms are in-
volved in this aspect. We have shown previously that
PPARα
2.52
PPARγ
*
A B
C D
**
* *
1.5
2
1
1.5
m
R
N
A
 (%
co
nt
ro
l)
0
0.5
1
0
0.5
Control EXE + W EXE +
CompC
EXE +
Rp
Control Exe Exe
+ Rp
Exe
+ W
Exe +
Comp C
EXE
CPT1A
*
2
2.5
ACOX1
*
2
2.5
1
1.5
1
1.5
0
0.5
Control Exe Exe
+ Rp
Exe
+ W
Exe +
Comp C
Control Exe Exe
+ Rp
Exe
+ W
Exe +
Comp C
0
0.5m
R
N
A
 (%
co
nt
ro
l)
Fig. 8. Effect of the protein kinase A (PKA)-inhibitor Rp-c-AMP (Rp, 100mmol/L), the PI3K-inhibitor wortmannin (W, 100 nM) and the AMPK
inhibitor compound C (CompC, 20mM) on peroxisome proliferator-activated receptor g (PPARg) (A), peroxisome proliferator-activated receptor
a (PPARa) (B), its downstream genes acyl-coenzyme A oxidase 1-palmitoyl (ACOX1) (C) and carnitine palmitoyltransferase 1A (CPT1A) (D)
mRNA expression in cultured hepatocytes isolated from rats with nonalcoholic steatohepatitis (NASH). Isolated hepatocytes were cultured
overnight and then incubated for additional 24 h with the same medium containing (black bars) or not (white bars, control) 100 nM exenatide.
In parallel experiments, cells were also pre-incubated for 30 min at 37 1C with either Rp-c- AMP, wortmannin or compound C. Total RNA was
extracted and quantified by RT-PCR. Data are expressed as mean SD of fold increase compared with controls. Po0.05 vs controls.
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high-fat diet significantly reduced hepatic PPARa expres-
sion (15) and this is confirmed in the present study where
reduced expression of its downstream target genes
ACOX1 (a rate-limiting enzyme in peroxisomal FFA b-
oxidation) and CPT1A (a key enzyme in mitochondrial
b-oxidation of FFA) was observed. In parallel, high-fat
diet significantly reduced also PPARg expression and
increased JNK activation that is able to induce insulin
resistance through Ser307 IRS1 phosphorylation (15). We
thus took advantage from this in vivo model of NASH to
show that these alterations were overall reversed by
incubation of NASH hepatocytes with exenatide. Because
PPARa acts on FFA oxidation and PPARg regulates lipid
homeostasis and insulin sensitivity (42) we thus hy-
pothesized that exenatide ameliorates the impairment in
hepatic FFA metabolism and oxidation induced by high-
fat diet. This was confirmed in our study by the observa-
tion that the total amount of fatty acids in hepatocytes
from rats with NASH was reduced by 30% after GLP-1r
activation. This result is also supported by the fact that
pioglitazone (a PPARg agonist) improves lipid metabo-
lism as well as liver histology (43) and that FFA stimula-
tion of GPR120, a G-protein-coupled receptor expressed
abundantly by the intestine, promotes GLP-1 secretion
and increases circulating insulin levels (44). In this
regard, insulin resistance is associated to increased
Ser307 JNK phosphorylation, which inhibits the insulin
receptor signalling (15, 45). GLP1-r activation by exena-
tide was able to reduce the level of JNK phosphorylation
in hepatocytes during NASH. This effect was PPARg-
dependent, but PPARa-independent (Fig. 9). Also in
agreement with our data, rosiglitazone (a PPARg ligand)
inhibits TNFa-induced JNK activation in adipocytes and
enhances insulin sensitivity (46).
G-protein coupled receptors, such as GLP-1r, act through
a cAMP-dependent activation of PKA (19). Increased
cAMP levels have been observed in hepatocytes isolated
from normal rats after incubation with exenatide (36).
Active PKA represents a docking site for several downstream
transduction pathways. Incubation with exenatide resulted
in a marked increase in active PKA formation in hepato-
cytes isolated from high-fat diet-treated rats, from which
signal diverged to activate AMPK and the ERK/PI3K path-
way needed to transduce the message to PPARs. In agree-
ment with our data, Gupta and colleagues recently used in
vitro experiments to demonstrate GLP1-r internalization in
hepatocyte cell lines. Following this, exenatide activated the
docking protein PDK1 from which the signal diverged to
phosphorylate Akt and PKC-z, making reasonable an effect
on GLUT2 synthesis and decreasing glycogen and fatty acid
synthesis (11). Thus, these and our data unequivocally
demonstrate, by using different experimental approaches,
that eventide is able to directly induce different intracellular
signalling events that counteract the metabolic pathways
altered in the course of NAFLD and NASH.
In summary, our experiments indicate that GLP-1r is
expressed in human liver and its expression is decreased
in patients with NASH. In hepatocytes isolated from rats
with NASH, the signalling cascade involved in stimula-
tion of hepatic fatty acid oxidation and insulin sensitivity
is impaired and GLP1-r activation with exenatide ame-
liorated these defects. By activating specific intracellular
kinases such as PI3K and AMPK, exenatide determined:
(i) increased PPARa activity, which induced transcrip-
tions of ACOX1 and CPT1A (both involved in fatty acid
b-oxidation) and reduced the total amount of fatty acids
in hepatocytes; (ii) increased PPARg expression that
exerted its insulin-sensitizing action by reducing Ser307
JNK phosphorylation. Thus, our data indicate that GLP-
1 analogues, currently used in the treatment of type 2
diabetes, are a promising treatment approach to improve
hepatic insulin resistance and fatty acid b-oxidation also
in patients with NAFLD/NASH.
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